Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
EU legal act included in a Joint Committee Decision (JCD); entry into force of the Decision is pending fulfilment of constitutional requirements by Iceland, Liechtenstein and/or Norway pursuant to Article 103 EEA
Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XIII Medicinal Products
Joint committee decision (JCD)
167/2024
Legal Documents
Regulation (EU) 2022/123 of the European Parliament and of the Council of 25 January 2022 on a reinforced role for the European Medicines Agency in crisis preparedness and management for medicinal products and medical devices
Reglugerð Evrópuþingsins og ráðsins (ESB) 2022/123 frá 25. janúar 2022 um að styrkja hlutverk Lyfjastofnunar Evrópu að því er varðar viðbúnað við krísu og krísustjórnun varðandi lyf og lækningatæki
Verordnung (EU) 2022/123 des Europäischen Parlaments und des Rates vom 25. Januar 2022 zu einer verstärkten Rolle der Europäischen Arzneimittel-Agentur bei der Krisenvorsorge und -bewältigung in Bezug auf Arzneimittel und Medizinprodukte
History
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.